100
Participants
Start Date
June 30, 2012
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Adalimumab, current formulation
Current formulation adalimumab 40 mg every other week
Adalimumab, new formulation
New formulation adalimumab 40 mg every other week
Site Reference ID/Investigator# 75100, Brussels
Site Reference ID/Investigator# 75101, Liège
Site Reference ID/Investigator# 83133, Philadelphia
Site Reference ID/Investigator# 75074, Charleston
Site Reference ID/Investigator# 78014, Ratingen
Site Reference ID/Investigator# 75076, Wichita
Site Reference ID/Investigator# 75073, Mesa
Site Reference ID/Investigator# 75077, Hemet
Site Reference ID/Investigator# 76934, Banská Bystrica
Site Reference ID/Investigator# 76433, Ploieşti
Site Reference ID/Investigator# 75978, Cluj-Napoca
Site Reference ID/Investigator# 75075, Clifton
Site Reference ID/Investigator# 75104, Brno
Site Reference ID/Investigator# 76788, Prague
Site Reference ID/Investigator# 75102, Uherské Hradiště
Site Reference ID/Investigator# 75103, Zlín
Site Reference ID/Investigator# 75079, Caguas
Site Reference ID/Investigator# 75078, Vega Baja
Site Reference ID/Investigator# 76787, Bucharest
Site Reference ID/Investigator# 76935, Senica
Site Reference ID/Investigator# 76682, Žilina
AbbVie (prior sponsor, Abbott)
INDUSTRY